Verrica Pharmaceuticals Inc.

As of June 30, 2026, Verrica Pharmaceuticals Inc. carries a market capitalization of 105.13M, placing it among publicly traded companies globally. Its enterprise value stands at 95.75M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Verrica Pharmaceuticals Inc.'s next confirmed earnings release is scheduled for November 9, 2026.

As of June 30, 2026, Verrica Pharmaceuticals Inc. has 17.18M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.34, and the price-to-book ratio stands at 24.41.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.16 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 95.75M versus a market cap of 105.13M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Verrica Pharmaceuticals Inc. maintains a current ratio of 1.45, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 42.02, indicating elevated leverage, while an interest coverage ratio of -7.40 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -83.02, reflecting losses generated across the asset base. The company generates approximately 405,632.11 in revenue per employee across its workforce of 74.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.63 indicates how many times Verrica Pharmaceuticals Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Verrica Pharmaceuticals Inc.'s stock has declined approximately 2.05% over the past 52 weeks. The 50-day moving average sits at 4.58, while the 200-day moving average is 5.74.

Over the twelve months ended June 30, 2026, Verrica Pharmaceuticals Inc. generated 30.32M in revenue and converted that into -31.18M in net income, yielding earnings per share of -1.88. EBITDA reached -27.60M, while operating income came in at -26.43M.

As of June 30, 2026, Verrica Pharmaceuticals Inc. holds 11.20M in cash and equivalents against 1.81M in total debt, resulting in a net debt position of -11.20M. Total book value stands at 4.31M, with working capital of 10.20M providing operational flexibility.

Verrica Pharmaceuticals Inc. produced -13.35M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -13.35M - equivalent to -0.81 per share.

Over the twelve months ended June 30, 2026, Verrica Pharmaceuticals Inc. posted a gross margin of 85.89, reflecting its pricing power and cost economics. The operating margin of -87.18 and net profit margin of -102.84 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -13.18: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -8.95, meaning Verrica Pharmaceuticals Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Verrica Pharmaceuticals Inc.'s most recent stock split took place on July 25, 2025 with a 10:1 split ratio.

As of June 30, 2026, Verrica Pharmaceuticals Inc. has an Altman Z-Score of -12.77, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.